The remaining 618 patients with symptoms of dyspepsia were randomized to receive pharmacotherapy by either mosapride (311 patients) or teprenone (307 patients) (Fig. 2). There were no significant ...

No serious side effects or abnormal laboratory findings were observed for either mosapride or teprenone. Therefore, we believe that the 5-HT 4 agonist, mosapride, can be a first-line drug to treat FD.